Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF Trial

Keyphrases

• Metabolic Profiling 100%
• Heart Failure with Preserved Ejection Fraction (HFpEF) 100%
• Targeted Proteomics 100%
• Heart Failure Trials 100%
• Dapagliflozin 100%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 66%
• Ketones 66%
• Heart Failure 50%
• HF with Preserved Ejection Fraction 50%
• Negatively Associated 50%
• Placebo 33%
• Branched-chain Amino Acids 33%
• Principal Coordinate Analysis (PCoA) 33%
• N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) 33%
• Metabolic 16%
• Novel Therapeutic Targets 16%
• Metabolic Pathway 16%
• Placebo-controlled 16%
• Metabolic Signature 16%
• Placebo-controlled Trial 16%
• Ejection Fraction 16%
• Fatty Acid Metabolism 16%
• Metabolic Biomarkers 16%
• Fatty Acid Metabolites 16%
• No Significant Difference 16%
• 6-minute Walk Test (6MWT) 16%
• Branched-chain Keto Acids 16%
• Change in Weight 16%
• Circulating Metabolites 16%
• Fatty Acid Chain 16%
• Combined Treatment 16%
• Linear Regression 16%
• Markers of Disease Severity 16%
• Treatment Interaction 16%
• Test Distance 16%
• Target Profiling 16%
• Heart Failure with Reduced EF 16%
• Long-chain Acylcarnitines 16%
• Amino Acid Pathway 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Heart Failure with Preserved Ejection Fraction 100%
• Congestive Heart Failure 100%
• Dapagliflozin 100%
• Placebo 66%
• Sodium Glucose Cotransporter 2 Inhibitor 66%
• Fatty Acid 50%
• Natriuretic Factor 33%
• Branched Chain Amino Acid 33%
• Heart Failure with Reduced Ejection Fraction 16%
• Biological Marker 16%
• Disease Severity 16%
• Acylcarnitine 16%
• Oxoacid 16%